[1]CurrentPatentAssignee:EISAICOLTD-EP1889836,2008,A1Locationinpatent:Page/Pagecolumn59
53617-36-0
[1]Patent:EP1889836,2008,A1.Locationinpatent:Page/Pagecolumn59;60
[1]CurrentPatentAssignee:EISAICOLTD-US2008/214815,2008,A1Locationinpatent:Page/Pagecolumn24-25
[1]CurrentPatentAssignee:EISAICOLTD-US2008/214815,2008,A1Locationinpatent:Page/Pagecolumn25
Title: Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Journal: Molecular cancer therapeutics 20121001
Title: Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Journal: The American journal of pathology 20120901
Title: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120701
Title: Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120315
Title: E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.
Journal: Cancer science 20100101
Title: Nakagawa T et al. E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci, 2010, 101(1), 210-215.
Title: Wang W et al. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin Cancer Res, 2012, 18(6), 1663-1671.
